bioRxiv Science⌕ Search

Biology subjects

Izquierdo, G.

Publications and source records attributed to Izquierdo, G..

2 recordsLinked to original sources

Changing dynamics of Aedes aegypti invasion and vector-borne disease risk for rural communities in the Peruvian Amazon

Aedes aegypti, the primary vector of dengue virus, is predominantly considered an urban mosquito, especially in the Americas, where its reemergence began in cities after the end of continent-wide eradication campaigns. The results of our study diverge from this narrative, demonstrating the recent and widespread rural invasion of Ae. aegypti along major shipping routes in the northern Peruvian Amazon between the major cities of Iquitos, Pucallpa, and Yurimaguas. We identified Ae. aegypti populations in 29 of 30 sites surveyed across a rural to urban gradient and characterized mosquito larval habitats and Ae. aegypti adult metrics. Households, regardless of community size, were more likely to be positive for Ae. aegypti adult(s) and had a higher number of Ae. aegypti adults if a mosquito larval habitat was identified on the property, compared to houses without a larval habitat. In multiple instances, adult Ae. aegypti indices in rural villages were equal to or greater than indices in dengue-endemic cities, suggesting the entomological risk level in some rural areas is sufficient to sustain dengue transmission. Fourteen rural sites were sampled in transects from the community river port into town. In seven of these sites, houses closer to the port were significantly more likely to be infested with Ae. aegypti adults than houses further from the ports, and four additional sites had a marginal relationship to the same effect. This pattern suggests that many rural sites are invaded via adult Ae. aegypti disembarking from boats at the port, finding nearby oviposition sites, and advancing stepwise into town. The existence of the pattern also suggests that many of the sites are still experiencing active invasion, with sections of towns still Ae. aegypti-free. Only one site shows a strong signal of invasion via the egg or larval stage, with a focus of Ae. aegypti far removed from the port. The widespread infestation of Ae. aegypti in rural areas is a major public health threat given the far distance of communities to hospital care. It is important to implement control measures now before the mosquito gains a stronger foothold in zones of active invasion.

ecology↗

Immunotherapy prevents long-term disability in relapsing multiple sclerosis over 15 years

ObjectiveWhether immunotherapy improves long-term disability in multiple sclerosis has not been satisfactorily demonstrated. This study examined the effect of immunotherapy on long-term disability outcomes in relapsing-remitting multiple sclerosis.\n\nMethodsWe studied patients from MSBase followed for [≥]1 year, with [≥]3 visits, [≥]1 visit per year and exposed to a multiple sclerosis therapy, and a subset of patients with [≥]15-year follow-up. Marginal structural models were used to compare the hazard of 12-month confirmed increase and decrease in disability, EDSS step 6 and the incidence of relapses between treated and untreated periods. Marginal structural models were continuously re-adjusted for patient age, sex, pregnancy, date, disease course, time from first symptom, prior relapse history, disability and MRI activity.\n\nResults14,717 patients were studied. During the treated periods, patients were less likely to experience relapses (hazard ratio 0.60, 95% confidence interval 0.43-0.82, p=0.0016), worsening of disability (0.56, 0.38-0.82, p=0.0026) and progress to EDSS step 6 (0.33, 0.19-0.59, p=0.00019). Among 1085 patients with [≥]15-year follow-up, the treated patients were less likely to experience relapses (0.59, 0.50-0.70, p=10-9) and worsening of disability (0.81, 0.67-0.99, p=0.043).\n\nConclusionsContinued treatment with multiple sclerosis immunotherapies reduces disability accrual (by 19-44%), the risk of need of a walking aid by 67% and the frequency of relapses (by 40-41%) over 15 years. A proof of long-term effect of immunomodulation on disability outcomes is the key to establishing its disease modifying properties.

neuroscience↗